Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.

Abstract

CONTEXT:

The optimal unfractionated heparin regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes treated with fondaparinux is uncertain.

OBJECTIVE:

To compare the safety of 2 unfractionated heparin regimens during PCI in high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.

DESIGN, SETTING, AND PARTICIPANTS:

Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010.

INTERVENTIONS:

Patients received intravenously either low-dose unfractionated heparin, 50 U/kg, regardless of use of glycoprotein IIb/IIIa (GpIIb-IIIa) inhibitors or standard-dose unfractionated heparin, 85 U/kg (60 U/kg with GpIIb-IIIa inhibitors), adjusted by blinded activated clotting time (ACT).

MAIN OUTCOME MEASURES:

Composite of major bleeding, minor bleeding, or major vascular access-site complications up to 48 hours after PCI. Key secondary outcomes include composite of major bleeding at 48 hours with death, myocardial infarction, or target vessel revascularization within day 30.

RESULTS:

The primary outcome occurred in 4.7% of those in the low-dose group vs 5.8% in the standard-dose group (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.54-1.19; P = .27). The rates of major bleeding were not different but the rates of minor bleeding were lower with 0.7% in the low-dose group vs 1.7% in the standard-dose group (OR, 0.40; 95% CI, 0.16-0.97; P = .04). For the key secondary outcome, the rates for low-dose group were 5.8% vs 3.9% in the standard-dose group (OR, 1.51; 95% CI, 1.00-2.28; P = .05) and for death, myocardial infarction, or target vessel revascularization it was 4.5% for the low-dose group vs 2.9% for the standard-dose group (OR, 1.58; 95% CI, 0.98-2.53; P = .06). Catheter thrombus rates were very low (0.5% in the low-dose group and 0.1% in the standard-dose group, P = .15).

CONCLUSION:

Low-dose compared with standard-dose unfractionated heparin did not reduce major peri-PCI bleeding and vascular access-site complications.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00790907.

• Authors: FUTURA/OASIS-8 Trial Group, Philippe Gabriel Steg, Sanjit S Jolly, Shamir R Mehta, Rizwan Afzal, Denis Xavier, Hans-Jurgen Rupprecht, Jose L López-Sendón, Andrzej Budaj, Rafael Diaz, Alvaro Avezum, Petr Widimsky, Sunil V Rao, Susan Chrolavicius, Brandi Meeks, Campbell Joyner, Janice Pogue, Salim Yusuf
• Journal: JAMA (JAMA) Vol. 304 Issue 12 Pg. 1339-49 (Sep 22 2010) ISSN: 1538-3598 [Electronic] United States
• PMID: 20805623 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants
• Polysaccharides
• Heparin
• Fondaparinux

Topics

• Acute Coronary Syndrome (therapy)
• Aged
• Angioplasty, Balloon, Coronary
• Anticoagulants (administration & dosage)
• Catheters, Indwelling (adverse effects)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Fondaparinux
• Hemorrhage (chemically induced, prevention & control)
• Heparin (administration & dosage)
• Humans
• Male
• Middle Aged
• Polysaccharides (therapeutic use)